LPAAT-δ Activators
LPAAT-δ Activators represent a group of chemicals that can influence the activation of LPAAT-δ, also known as AGPAT4, a key enzyme involved in phospholipid synthesis. Insulin, a regulator of lipid metabolism, can enhance lipid synthesis, possibly leading to a greater demand for AGPAT4 activity. Metformin, an activator of AMPK, can introduce changes in lipid synthesis pathways, thus having an indirect effect on AGPAT4.
Agents like rosiglitazone, pioglitazone, and troglitazone, all PPARγ agonists, regulate lipid storage and metabolism, which can indirectly affect AGPAT4-related processes. Similarly, fenofibrate, as a PPARα agonist, affects fatty acid oxidation, which in turn can modulate AGPAT4's role in lipid synthesis. L-carnitine, crucial for fatty acid transport into mitochondria, can affect fatty acid availability, influencing AGPAT4's lipid synthesis role. Other chemicals like Coenzyme Q10, with its pivotal role in the electron transport chain, and berberine, an AMPK activator, also play roles in lipid metabolism, which can influence AGPAT4's activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Insulin | 11061-68-0 | sc-29062 sc-29062A sc-29062B | 100 mg 1 g 10 g | $156.00 $1248.00 $12508.00 | 82 | |
Insulin regulates lipid metabolism, and AGPAT4 is involved in phospholipid synthesis. Enhanced lipid synthesis under insulin signaling could indirectly stimulate AGPAT4 activity. | ||||||
Metformin-d6, Hydrochloride | 1185166-01-1 | sc-218701 sc-218701A sc-218701B | 1 mg 5 mg 10 mg | $292.00 $822.00 $1540.00 | 1 | |
Metformin activates AMPK, a key regulator of lipid metabolism. AMPK activation could lead to changes in lipid synthesis pathways, possibly influencing AGPAT4 activity. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $120.00 $326.00 $634.00 $947.00 $1259.00 | 38 | |
As a PPARγ agonist, rosiglitazone modulates lipid storage and metabolism. This modulation might indirectly affect AGPAT4-related pathways. | ||||||
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $55.00 $125.00 | 13 | |
Similar to rosiglitazone, pioglitazone is a PPARγ agonist. Changes in lipid metabolism could influence the role or activity of AGPAT4. | ||||||
Fenofibrate | 49562-28-9 | sc-204751 | 5 g | $41.00 | 9 | |
A PPARα agonist, fenofibrate affects fatty acid oxidation. Altered lipid flux might indirectly modulate AGPAT4's role in lipid synthesis. | ||||||
Troglitazone | 97322-87-7 | sc-200904 sc-200904B sc-200904A | 5 mg 10 mg 25 mg | $110.00 $204.00 $435.00 | 9 | |
Troglitazone, another PPARγ agonist, affects lipid storage. This could indirectly have an impact on AGPAT4 activity through altered lipid synthesis demands. | ||||||
Adenosine phosphate(Vitamin B8) | 61-19-8 | sc-278678 sc-278678A | 50 g 100 g | $160.00 $240.00 | ||
AMP can activate the AMPK pathway, which has downstream effects on lipid metabolism. Any modulation in lipid synthesis could affect AGPAT4. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
AICAR is an AMPK activator. By modulating lipid metabolism through AMPK activation, AICAR might have an indirect impact on AGPAT4 activity. | ||||||
L-Carnitine | 541-15-1 | sc-205727 sc-205727A sc-205727B sc-205727C | 1 g 5 g 100 g 250 g | $23.00 $34.00 $79.00 $179.00 | 3 | |
L-carnitine plays a role in fatty acid transport into mitochondria for oxidation. Changes in fatty acid availability could influence AGPAT4's lipid synthesis role. | ||||||
Coenzyme Q10 | 303-98-0 | sc-205262 sc-205262A | 1 g 5 g | $71.00 $184.00 | 1 | |
CoQ10 is crucial for the electron transport chain and affects lipid metabolism. Its modulation of lipid metabolic pathways could influence AGPAT4. | ||||||